Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Thalidomide has been identified as having mild activity as an angiogenesis inhibitor in some cancers. A newer version of this medication is lenalidomide (Revlimid), which has fewer side effects than thalidomide.
Another medication, bevacizumab (Avastin®), has been approved by the US Food and Drug Administration (FDA) to aid in the treatment of colorectal, lung, and some other cancers. Two newer additions to antiangiogenesis therapy include sunitinib (Sutent®) and sorafenib (Nexavar®). Many other angiogenesis inhibitors are now being studied as well.